Cellmidi is a pioneering brand that offers affordable and accessible cell and gene therapy solutions to address unmet medical needs across the globe. As a preclinical-stage biotechnology spin-off from Chulalongkorn University, we specialize in developing novel gene-edited immune cell products for cancer treatment. Our focus is on enhancing CAR T cell treatment outcomes in solid tumors by tackling immune suppression within the tumor niche through our cutting-edge PLUS CAR T technology.

By integrating our proprietary endodomain into second-generation CAR constructs, we boost cellular proliferation, cytotoxicity, and persistence while minimizing exhaustion. Our innovative CAR T cell platform shows promise in effectively targeting various types of solid tumors, potentially revolutionizing solid tumor therapy. Led by a dedicated team of experts, including executives like Koramit Suppipat and Supannikar Tawinwung, Cellmidi is at the forefront of advancing the field of cell and gene therapy